Miniatura

Fitxers

Long-term follow-up of certolizumab_RheumaticAndMusculoskeletal.pdf (652.24 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-07-06

Llicència de publicació

cc by-nc (c) Martín Varillas, José Luis et al, 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/209286

Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1136/rmdopen-2022-002693

Resum

Objectives: To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID).MethodsMulticentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year.ResultsWe studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6 +/- 11.7 years. The IMID included were: spondyloarthritis (n=43), Behcet's disease (n=10), psoriatic arthritis (n=8), Crohn's disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1),ConclusionsCZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.

Matèries

Malalties autoimmunitàries, Immunoteràpia

Matèries (anglès)

Autoimmune diseases, Immunotheraphy

Citació

Col·leccions

Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

MARTÍN VARILLAS, José luis, SÁNCHEZ BILBAO, Lara, CALVO RÍO, Vanesa, ADÁN CIVERA, Alfredo, HERNANZ, Inés, GALLEGO FLORES, Adela, BELTRAN CATALAN, Emma, CASTRO OREIRO, Sonia, FANLO, Patricia, GARCÍA MARTOS, Álvaro, TORRE, Ignacio, CORDERO COMA, Miguel, DIOS, Juan ramón de, GARCÍA APARICIO, Ángel, HERNÁNDEZ GARFELLA, Marisa, SÁNCHEZ ANDRADE, Amalia, GARCÍA VALLE, Andrea, MAIZ ALONSO, Olga, MIGUÉLEZ, Roberto, RODRÍGUEZ MONTERO, Sergio, URRUTICOECHEA ARANA, Ana, VEROZ, Raúl, CONESA, Arantxa, FERNÉNDEZ CARBALLIDO, Cristina, JOVANÍ, Vega, MONDEJAR, José j., MARTÍNEZ GONZÁLEZ, Olga, MOYA ALVARADO, Patricia, ROMERO YUSTE, Susana, RUBIO MUÑOZ, Paula, PEÑA SAINZ-PARDO, Eva, GARIJO BUFORT, Marta, DEMETRIO PABLO, Rosalía, HERNÁNDEZ, José l., BLANCO, Ricardo. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients. _Rheumatic and Muskuloskeletal Diseases Open_. 2022. Vol. 8, núm. 2. [consulta: 24 de gener de 2026]. ISSN: 2056-5933. [Disponible a: https://hdl.handle.net/2445/209286]

Exportar metadades

JSON - METS

Compartir registre